Over a third of our vaccines currently in development aim to help protect against diseases for which there are no vaccines currently available, including HIV and TB.3

Delivering GSK’s vaccines to the developing world

Children in developing countries are more likely to die before the age of five than children in developed countries1 from vaccine-preventable diseases.

We have committed to provide Gavi, the Vaccine Alliance, with more than 850 million vaccine doses at reduced prices to help protect 300 million children in the developing world by 2024.4

Our pneumococcal vaccine was introduced in developing countries in Africa just 18 months after its introduction in Europe.

We’ve been a foundation provider of oral polio vaccines to UNICEF for 50 years, having already contributed over 16 billion doses since the establishment of the Global Polio Eradication Initiative in 1988.

Our vaccine for pneumococcal disease has now been introduced in 13 Gavi countries. In total we delivered 62 million doses in 2015, reaching a total of 182 million doses since 2010.3

Our agreement with Médecins Sans Frontières to supply low-cost doses of our pneumococcal vaccine to immunise children caught up in ongoing crises has seen over 100,000 doses delivered over the course of 2015.3

In 2014 we were ranked in the Access to Medicine Index

Over a third of our vaccines currently in development aim to help protect against diseases for which there are no vaccines currently available, including HIV and TB.3

We have committed to provide Gavi, the Vaccine Alliance, with more than 850 million vaccine doses at reduced prices to help protect 300 million children in the developing world by 2024.4

In 2015, we committed to freezing our prices for developing countries that graduate from Gavi support, so they can continue to purchase our vaccines at discounted prices for another decade.3

Our tiered pricing approach...

In 2015, we committed to freezing our prices for developing countries that graduate from Gavi support, so they can continue to purchase our vaccines at discounted prices for another decade.3

In 2015, the World Health Organization listed our malaria vaccine RTS,S as a promising candidate for the next generation of malaria vaccines.

We have been working to develop a malaria vaccine with partners for the past 30 years to help protect children from this deadly parasite.

Looking to the future

Other examples include our malaria vaccine. In 2015 our malaria vaccine RTS,S received a positive scientific opinion from the EMA for children aged six months to 17 months.1

These statements are to the best of our knowledge correct at the time of writing. However, the scientific evidence and clinical data base are continually evolving. Always see the most up-to-date information at gsk.com

2 Children in developing countries are 10x more likely to die before the age of five than children in developed countries1 from vaccine-preventable diseases.